Combination phentermine and topiramate extended release in the management of obesity

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 8, 2015, Pages 1263-1274

  Alfaris, Nasreen ^a   Minnick, Alyssa M ^a   Hopkins, Christina M ^a   Berkowitz, Robert I ^a   Wadden, Thomas A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Lifestyle modification; Overweight; Pharmacotherapy; Weight loss medication

Indexed keywords

PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; TOPIRAMATE; ANTIOBESITY AGENT; DELAYED RELEASE FORMULATION; DRUG COMBINATION; FRUCTOSE;

ARTHRALGIA; ARTICLE; BACKACHE; BLURRED VISION; BODY WEIGHT MANAGEMENT; BRONCHITIS; CARDIOVASCULAR RISK; CHEMICAL ANALYSIS; CLINICAL TRIAL (TOPIC); CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG RELEASE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSGEUSIA; EXTENDED RELEASE; FATIGUE; HEADACHE; HUMAN; INSOMNIA; LIFESTYLE MODIFICATION; MONOTHERAPY; NAUSEA; OBESITY; PARESTHESIA; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; RISK ASSESSMENT; RISK FACTOR; SINUSITIS; SLEEP DISORDERED BREATHING; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WEIGHT REDUCTION; XEROSTOMIA; ANALOGS AND DERIVATIVES; CARDIOVASCULAR DISEASES; DELAYED RELEASE FORMULATION; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; DRUG COMBINATION; LIFESTYLE;

ANTI-OBESITY AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; DRUG COMBINATIONS; FRUCTOSE; HUMANS; LIFE STYLE; OBESITY; PHENTERMINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; WEIGHT LOSS;

EID: 84929166172     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1041505     Document Type: Article

References (59)

1. National Task Force on Prevention and Treatment of Obesity. Overweight, obesity, and health risk. Arch Intern Med 2000;160:898-904
2. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307:491-7
3. James WP. The epidemiology of obesity: the size of the problem. J Intern Med 2008;263:336-52
4. Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011;34:1481-6
5. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
6. Executive summary: Guidelines (2013) for the management of overweight and obesity in adults: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the Obesity Society published by the Obesity Society and American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Based on a systematic review from the The Obesity Expert Panel, 2013. Obesity (Silver Spring) 2014;22(Suppl 2):S5-39
7. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005;353:2111-20
8. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-8
9. James WPT, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363:905-17
10. Colman E. Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann Intern Med 2005;143:380-5
11. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014;311:74-86
12. Leblanc ES, O'Connor E, Whitlock EP, et al. Effectiveness of primary carerelevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:434-47
13. Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335:1194-9
14. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61
15. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363:245-56
16. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011;96:3067-77
17. Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 2009;17:30-9
18. Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 2013;21:935-43
19. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376:595-605
20. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/ bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011;19:110-20
21. Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606-16
22. Cameron F, Whiteside G, McKeage K. Phentermine and topiramate extended release (Qsymia): first global approval. Drugs 2012;72:2033-42
23. Cosentino G, Conrad AO, Uwaifo GI. Phentermine and topiramate for the management of obesity: a review. Drug Des Devel Ther 2013;7:267-78
24. Garvey WT. Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management. Expert Opin Drug Saf 2013;12:741-56
25. Shin JH, Gadde KM. Clinical utility of phentermine/topiramate (Qsymia) combination for the treatment of obesity. Diabetes Metab Syndr Obes 2013;6:131-9
26. Smith SM, Meyer M, Trinkley KE. Phentermine/topiramate for the treatment of obesity. Ann Pharmacother 2013;47:340-9
27. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/ topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012;20:330-42
28. Xiong GL, Gadde KM. Combination phentermine/topiramate for obesity treatment in primary care: a review. Postgrad Med 2014;126:110-16
29. O'Neil MJ. editors. The merck index-an encyclopedia of chemicals, drugs, and biologicals. 13th edition. Merck and Co., Inc; Whitehouse Station, NJ: 2001
30. National Center for Biotechnology Information. PubChem Compound Database CID=4771 Available from: http://pubchem.ncbi.nlm.nih.gov/ compound/phentermine [Accessed on 16 December 2014]
31. Qsymia [package insert]. VIVUS, Inc; Mountain View, CA 2014
32. Osol A, Hoover JE, Anderson JT. Remington's Pharmaceutical Sciences. 15 edition. Mack Publishing Co; Pennsylvania: 1975. p. 824
33. Munro JF, MacCuish AC, Wilson EM, Duncan LJ. Comparison of continuous and intermittent anorectic therapy in obesity. BMJ 1968;1:352-4
34. Kelly EM, Tungol AA, Wesolowicz LA. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss. J Manag Care Pharm 2013;19:642-54
35. Shank RP, Maryanoff BE. Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate. CNS Neurosci Ther 2008;14:120-42
36. Bays H. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease. Expert Rev Cardiovasc Ther 2010;8:1777-801
37. Hendricks EJ, Greenway FL, Westman EC, Gupta AK. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Silver Spring) 2011;19:2351-60
38. Rosenstock J, Hollander P, Gadde KM, et al. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care 2007;30:1480-6
39. Tonstad S, Tykarski A, Weissgarten J, et al. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am J Cardiol 2005;96:243-51
40. Verrotti A, Scaparrotta A, Agostinelli S, et al. Topiramate-induced weight loss: a review. Epilepsy Res 2011;95:189-99
41. Wilding J, Van Gaal L, Rissanen A, et al. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 2004;28:1399-410
42. Aronne LJ, Wadden TA, Peterson C, et al. Evaluation of phentermine and topiramate versus phentermine/ topiramate extended-release in obese adults. Obesity (Silver Spring) 2013;21:2163-71
43. Garvey WT, Ryan DH, Bohannon NJ, et al. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care 2014;37:3309-16
44. Winslow DH, Bowden CH, DiDonato KP, McCullough PA. A randomized, double-blind, placebocontrolled study of an oral, extendedrelease formulation of phentermine/ topiramate for the treatment of obstructive sleep apnea in obese adults. Sleep 2012;35:1529-39
45. Brownell KD. The LEARN program for weight management. The Life Style Co; Dallas: 2000
46. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlledrelease, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341-52
47. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95:297-308
48. Vivus, Inc. Vivus reports topline findings from FORTRESS. News release 2011. Available from: http://ir.vivus.com/ releasedetail.cfm?ReleaseID=634920 [Accessed 16 December 2014]
49. Vivus, Inc. VIVUS submits REMS amendment to FDA for Qsymia (Phentermine/topiramate extended release) capsule CIV. News release 2012. Available from: http://ir.vivus.com/ releasedetail.cfm?ReleaseID=714128 [Accessed 23 December 2014]
50. Colman E, Golden J, Roberts M, et al. The FDA's assessment of two drugs for chronic weight management. N Engl J Med 2012;367:1577-9
51. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724-37
52. Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008;299:316-23
53. Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA 2013;309:2240-9
54. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012;366:1577-85
55. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012;366:1567-76
56. O'Brien PE, McPhail T, Chaston TB, Dixon JB. Systematic review of mediumterm weight loss after bariatric operations. Obes Surg 2006;16:1032-40
57. Wadden TA, Womble LG, Sarwer DB, et al. Great expectations: "I'm losing 25% of my weight no matter what you say". J Consult Clin Psychol 2003;71:1084-9
58. Halpern B, Halpern A. Why are antiobesity drugs stigmatized? Expert Opin Drug Saf 2015;14:185-9
59. Bray GA. Why do we need drugs to treat the patient with obesity? Obesity (Silver Spring) 2013;21:893-9